DRUG DISCOVERY deste mês mostra simpósio sobre fusão e separação de companhias farmacêuticas.

1. go
Search Advanced search
The drug industry is facing major scientific and strategic challenges. Translating the hope of the
genomics revolution into new therapeutics has proven much more difficult than anticipated.
Meanwhile, generic competition is dramatically eroding revenues from established products, and
payers are placing increasing demands on drug-makers to demonstrate the economic benefits of
new drugs.
The impact on the industry is important not just for pharmaceutical and biotech companies, but for
the other stakeholders in drug research and development — from patients to governments. With
this in mind, this Nature Reprint Collection, presented on behalf of Eli Lilly and Company,
integrates in-depth analyses and expert perspectives to provide a comprehensive overview of the
factors underlying the challenges in drug innovation and the evolution of possible scientific and
strategic solutions.
Digital edition available at http://viewer.zmags.com/publication/81ab8b7c
Sponsor's foreword
Jan M. Lundberg, Ph.D.
Executive Vice President, Science and Technology
President, Lilly Research Laboratories
Download full foreword as PDF (186 KB)
Sponsor Feature
Eli Lilly and Company sponsor featureEli Lilly and Company sponsor feature
Collection Articles
How to improve R&D productivity: the pharmaceutical industry’s grand challenge.
Steven M. Paul et al.
doi:10.1038/nrd3078
Nature Reviews Drug Discovery 9, 203-214 (March 2010)
Abstract
Full Text
PDF (817 KB)
Network pharmacology: the next paradigm in drug discovery
Andrew L Hopkins
doi:10.1038/nchembio.118
Nature Chemical Biology 4, 682 - 690 (2008)
Abstract
Full Text
PDF (855 KB)
How were new medicines discovered?
David C. Swinney & Jason Anthony
doi:10.1038/nrd3480
Nature Reviews Drug Discovery 10, 507-519 (July 2011)
Abstract
Full Text

2. PDF (799 KB)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson, Eugen Dhimolea & Janice M. Reichert
doi:10.1038/nrd3229
Nature Reviews Drug Discovery 9, 767-774 (October 2010)
Abstract
Full Text
PDF (799 KB)
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing
variability of drug response
Hans-Georg Eichler et al.
doi:10.1038/nrd3501
Nature Reviews Drug Discovery 10, 495-506 (July 2011)
Abstract
Full Text
PDF (711 KB)
Innovative drug R&D in China
Jingzong Qi, Qingli Wang, Zhenhang Yu, Xin Chen1 & Fengshan Wang
doi:10.1038/nrd3435
>Nature Reviews Drug Discovery 10, 333-334 (May 2011)
Abstract
Full Text
PDF (711 KB)
The impact of mergers on pharmaceutical R&D
John L. LaMattina
doi:10.1038/nrd3514
Nature Reviews Drug Discovery 10, 559-560 (August 2011)
Abstract
Full Text
PDF (799 KB)
Crowd sourcing in drug discovery
Monika Lessl, Justin S. Bryans, Duncan Richards & Khusru Asadullah
doi:10.1038/nrd3412
Nature Reviews Drug Discovery 10, 241-242 (April 2011)
Abstract
Full Text
PDF (799 KB)
The future of drug development: advancing clinical trial design
John Orloff et al.
doi:10.1038/nrd3025
Nature Reviews Drug Discovery 8, 949-957 (December 2009)
Abstract
Full Text
PDF (799 KB)
The case for entrepreneurship in R&D in the pharmaceutical industry
Frank L. Douglas, V. K. Narayanan, Lesa Mitchell & Robert E. Litan
doi:10.1038/nrd3230

3. Nature Reviews Drug Discovery 9, 683-689 (September 2010)
Abstract
Full Text
PDF (799 KB)
topof page
Library Articles
Trends in the exploitation of novel drug targets
Mathias Rask-Andersen, Markus Sällman Almén & Helgi B. Schiöth
doi:10.1038/nrd3478
Nature Reviews Drug Discovery 10, 579-590 (August 2011)
Abstract
Full Text
PDF (949 KB)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli, Laura Magazzini & Massimo Riccaboni
doi:10.1038/nrd3405
Nature Reviews Drug Discovery 10, 428-438 (June 2011)
Abstract
Full Text
PDF (949 KB)
From the analyst's couch: US academic drug discovery
Stephen Frye, Marina Crosby, Teresa Edwards & Rudolph Juliano
doi:10.1038/nrd3462
Nature Reviews Drug Discovery 8, 865-878 (November 2009)
Full Text
PDF (950 KB)
Getting pharmaceutical R&D back on target
Mark E Bunnage
doi:10.1038/nchembio.581
Nature Chemical Biology 7, 335–339 (2011)
Abstract
Full Text
PDF (950 KB)
Managing the health of early-stage discovery
Michael Edwards, Tony Tramontin, Daniel Simon, Ajay Dhankhar & Mubasher Sheikh
doi:10.1038/nrd3388
Nature Reviews Drug Discovery 10, 171-172 (March 2011)
Abstract
Full Text
PDF (1006 KB)
Traditional drug-discovery model ripe for reform
Michael Edwards, Tony Tramontin, Daniel Simon, Ajay Dhankhar & Mubasher Sheikh
doi:10.1038/471017a
Nature 471, 17-18 (2011)
Abstract

4. Full Text
PDF (883 KB)
The problems with today's pharmaceutical business—an outsider's view
Mark Kessel
doi:10.1038/nbt.1748
Nature Biotechnology 29, 27–33 (2011)
Abstract
Full Text
PDF (950 KB)
Accessing new chemical space for 'undruggable' targets
Sivaraman Dandapani1 & Lisa A Marcaurelle
doi:10.1038/nchembio.479
Nature Chemical Biology 6, 861–863 (2010)
Abstract
Full Text
PDF (950 KB)
Location of pharmaceutical innovation: 2000–2009
Yali Friedman
doi:10.1038/nrd3298
Nature Reviews Drug Discovery 9, 835-836 (November 2010)
Abstract
Full Text
PDF (950 KB)
Lessons from 60 years of pharmaceutical innovation
Bernard Munos
doi:10.1038/nrd2961
Nature Reviews Drug Discovery 8, 959-968 (December 2009)
Abstract
Full Text
PDF (950 KB)
Can literature analysis identify innovation drivers in drug discovery?
Pankaj Agarwal & David B. Searls
doi:10.1038/nrd2973
Nature Reviews Drug Discovery 8, 865-878 (November 2009)
Abstract
Full Text
PDF (950 KB)
topof page
Extra navigation
Sponsor
Produced with support from Eli Lilly and Company

5. ADVERTISEMENT
Top
About NPG
Contact NPG
RSS web feeds
Help
Privacy policy
Legal notice
Accessibility statement
Terms

6. Nature News
Naturejobs
Nature Asia
Nature Education
go
Search:
© 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INA